SLC5A2 and metabolic dysfunction-associated steatohepatitis: Though the combination of SGLT2/GLP-1RA has already been evaluated in patients with T2D in several studies (AWARD 10 [85], Duration 8 [86], and AGATE [87]), there have been no studies evaluating the efficacy of combination therapy with these agents in the treatment of NASH.